Drugs / SRP-9005
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 3 | NCT06952686 | Jun 2025 → Nov 2030 | limb-girdle muscular dystrophy | Sarepta Therapeutics, Inc. | Withdrawn | No outcome recorded Stop: Business |
News releases announcing trial results or a regulatory action · 1
| Date | Issuer | Release |
|---|---|---|
| 2025-04-15 | Sarepta Therapeutics, Inc. | Regulatory Sarepta Therapeutics Announces Pipeline Progress for Multiple Limb-Girdle Muscular Dystrophy Programs sarepta.com ↗
A pre-Biologics License Application (BLA) meeting has occurred and the OTP has confirmed eligibility for the accelerated approval pathway for the program. |
All press releases naming this drug 1 release
| Date | Issuer | Release |
|---|---|---|
| 2025-04-15 | Sarepta Therapeutics, Inc. | Sarepta Therapeutics Announces Pipeline Progress for Multiple Limb-Girdle Muscular Dystrophy Programs sarepta.com ↗ |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | SRP-9005 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06952686 ↗ |
| Route | Intravenous | “single intravenous (IV) infusion” NCT06952686 ↗ |